Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies

Journal of Neurology Neurosurgery and Psychiatry

Volumn 66, Issue 5, 1999, Pages 612-616

  Hanna, Philip A ^a   Jankovic, Joseph ^a   Vincent, Angela ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Antibodies; Botulinum toxin; Dystonia; Immunoresistance

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; TOXIN ANTIBODY;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BIOASSAY; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; EYEBROW; FEMALE; FOREHEAD; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SERUM;

EID: 0032892281     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.66.5.612     Document Type: Article

References (23)

1. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991;324:1186-94.
2. Jankovic J. Use of botulinum toxin in neurology. In: Kennard C, ed. Recent advances in clinical neurology. Vol 8. Edinburgh: Churchill Livingstone, 1995;89-110.
3. American Academy of Neurology. Assessment: the clinical usefulness of botulinum toxin-A in treating neurological disorders; report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1990;40:1332-6.
4. American Academy of Ophthalmology. Botulinum toxin therapy of eye muscle disorders. Safety and effectiveness. Ophthalmology 1989;96(suppl):37-41.
5. Davidson BJ, Ludlow CL. Long-term effects of botulinum toxin injections in spasmodic dysphonia. Ann Otol Rhinol Laryngol 1996;105:33-42.
6. National Institutes of Health. Consensus development conference statement on clinical use of botulinum toxin. Arch Neurol 1991;48:1294-8.
7. Clarke CE. Therapeutic potential of botulinum toxin in neurologic disorders. Q J Med 1992;82:197-205.
8. Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 1990;53:633-9.
9. Berardelli A, Formica A, Mercuri B, et al. Botulinum toxin treatment in patients with focal dystonia and hemifacial spasm. A multicenter study of the Italian Movement Disorder Group. Ital J Neurol Sci 1993;14:361-7.
10. Geller BD, Hallett M, Ravits J. Botulinum toxin therapy in hemifacial spasm: clinical and electrophysiological studies. Muscle Nerve 1989;12:716-22.
11. Scott AB. Foreword. In: Jankovic J, Hallett M, eds. Therapy with botulinum toxin. New York: Marcel Dekker, 1994:vii-viii.
12. Zuber M, Sebald M, Bathien N, et al. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology 1993;43:1715-18.
13. Siatkowski RM, Tyutyunikov A, Biglan AW, et al. Serum antibody production to botulinum A toxin. Ophthalmology 1993;100:1861-6.
14. Hatheway CH, Dang C. Immunogenicity of the neurotoxins of Clostridium botulinum. In: Jankovic J, Hallett M, eds. Therapy with botulinum toxin. New York: Marcel Dekker, 1994:93-107.
15. Notermans S, Dufrenne J, Van Schothorst M. Enzyme-linked immunosorbent assay for detection of Clostridium botulinum toxin type A. Japan J Med Sci Biol 1978;31:81-5.
16. Notermans S, Nagel J. Assays for botulinum and tetanus toxins. In: Simpson LL, eds Botulinum neurotoxin and tetanus toxin. San Diego: Academic Press, 1989;319-331.
17. Shone C, Wilton-Smith P, Appleton N, et al. Monoclonal antibody-based immunoassay for type A Clostridium botulinum toxin is comparable to the mouse bioassay. Appl Environ Microbiol 1985;50:63-7.
18. Hanna PA, Jankovic J. Mouse bioassay versus western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology 1998;50:1624-9.
19. Palace J, Nairne A, Hyman N, et al. A radioimmunoprecipitation assay for antibodies to botulinum A. Neurology 1998; 50:1463-6.
20. Jankovic J, Schwartz, KS. Response and immunoresistance to botulinum toxin injections. Neurology 1995;45:1743-6.
21. Eleopra R, Tugnoli V, Rossetto O, et al. Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human. Neurosci Lett 1997;224:91-4.
22. Houser MK, Sheean GL, Lees AJ. Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A. J Neurol Neurosurg Psychiatry 1998;64:577-80.
23. Lew MF, Adomato BT, Duanne DD, et al. Botulinum toxin B (BotB): a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997;49:701-7.